Scholars@Duke
Matthew Wolf Foster

Matthew Wolf Foster

Associate Professor in Medicine
Medicine, Pulmonary, Allergy, and Critical Care Medicine
mwfoster@duke.edu
Duke Box 2613, Durham, NC 27710
Suite 320 Chesterfield Bldg, 701 W. Main St., Durham, NC 27701

Scholarly Works - Preprints

Effects of Non-Cardiac/Non-neurologic Surgery and Anaesthesia on the CSF Proteome, and Modulation by the APOE Mimetic Peptide CN-105.

Preprint · October 7, 2025 OBJECTIVE: To evaluate the effect of non-cardiac/non-neurologic surgery on the CSF proteome, and the effect of the APOE mimetic peptide CN-105 on postoperative CSF proteome changes. METHODS: We performed mass spectrometry-based proteomics on preoperative a ... Full text Link to item Cite

Mass spectrometry-based quantification of proteins and post-translational modifications in dried blood: longitudinal sampling of patients with sepsis in Tanzania.

Preprint · April 28, 2025 The proteomic analysis of blood is routine for disease phenotyping and biomarker development. Whole blood is commonly separated into soluble and cellular fractions. However, this can introduce pre-analytical variability; and analysis of a single component ... Full text Link to item Cite

A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma

Preprint · 2025 AbstractMany cancers evade immunosurveillance by downregulating surface major histocompatibility class (MHC)-I. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes MHC-I degradation and is elevated in glioma. Evolocumab is a ... Full text Cite

Analysis of Protein Cysteine Acylation Using a Modified Suspension Trap (Acyl-Trap).

Preprint · June 29, 2024 Proteins undergo reversible S-acylation via a thioester linkage in vivo. S-palmitoylation, modification by C16:0 fatty acid, is a common S-acylation that mediates critical protein-membrane and protein-protein interactions. The most widely used S-acylation ... Full text Link to item Cite

A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma

Preprint · 2024 Many cancers evade immunosurveillance by downregulating surface major histocompatibility class (MHC)-I. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes MHC-I degradation and is elevated in glioma. Evolocumab is a clinically approved PCSK9 in ... Full text Cite